6533b837fe1ef96bd12a33ba

RESEARCH PRODUCT

Ketogenic diet for infants with epilepsy: A literature review.

Eloisa GittoGiovanni CorselloAndrea D. PraticòMartino RuggieriGabriella D'angeloMassimo BarbagalloStefano CatanzaroPiero PavoneLaura MauceriRaffaele Falsaperla

subject

MalePediatricsmedicine.medical_specialtyDrug Resistant EpilepsyKetogenicmedicine.medical_treatmentDrug-resistant epilepsyDrug-resistant epilepsy Epilepsy Glucose transporter type 1 deficiency Infant Ketogenic diet Diet Ketogenic Disease Management Drug Resistant Epilepsy Epilepsy Female Glucose Transporter Type 1 Humans Infant. Infant Newborn. Male Seizures Treatment OutcomeNeonatal ageNewborn. MaleAge limitlaw.invention03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineRandomized controlled triallawSeizuresmedicineGlucose transporter type 1 deficiencyHumans030212 general & internal medicineProspective cohort studyGlucose Transporter Type 1Epilepsybusiness.industryInfant NewbornDisease ManagementInfantRetrospective cohort studyKetogenic dietInfant. InfantDrug Resistant Epilepsymedicine.diseaseDietTreatment OutcomeNeurologyFemaleNeurology (clinical)businessDiet Ketogenic030217 neurology & neurosurgeryKetogenic diet

description

Abstract The ketogenic diet (KD) is an established, nonpharmacological treatment for drug-resistant epilepsy (DRE). Actually, KD and its variants have been shown to be elective and resolute for patients with glucose transporter type 1 (GLUT1) deficiency. The aim of this review was to study the use of KD and its variants in infancy, including the neonatal age, and demonstrate the safety and efficacy of this treatment in patients with the age of 0–23 months affected by DRE already subjected to pharmacological approach attempts. A literature search was conducted using PubMed as the medical database source. We used the age limit of 0–23 months, and we considered only articles published between the years 2015 and 2018, in light of increasing interest worldwide in the use of KD and its variants to manage DRE. We included 52 publications: 1 Cochrane study, 22 retrospective studies, 9 prospective studies, 4 randomized controlled trials (RCTs), 12 clinical cases, and 4 clinical reviews. Literature data showed that KD and its variants are safe and useful in patients with the age of 0–23 months with DRE. Classical KD is of first choice in the treatment of GLUT1 deficiency. Earlier introduction of KD in GLUT1 promises a better outcome and a decrease in seizure frequency in these patients.

10.1016/j.yebeh.2020.107361https://pubmed.ncbi.nlm.nih.gov/33181904